Last updated on December 2018

Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel

Brief description of study

The purpose of this study is to evaluate the incidence of grade 3 neutropenia and/or neutropenic complications (febrile neutropenia, neutropenic infection) with two schedules of cabazitaxel (bi-weekly versus tri-weekly) plus prednisone in elderly men ( 70 years) with mCRPC previously treated with a docetaxel-containing regimen.

Detailed Study Description

Randomized, open-label, phase 3 trial in mCRPC patients aged 70 years.

  • Arm A : cabazitaxel 25 mg/m on Day 1 of a 3-week cycle plus daily prednisone or
  • Arm B: cabazitaxel 16 mg/m on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.
  • Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.
  • Standard cabazitaxel premedication will be used
  • Prophylactic G-CSF (GRANOCYTE) will be injected from Day 3 to Day 7 after every cycle of cabazitaxel if neutrophil count is> 2000/mm3, only 3 days).
  • All new hormonal treatment, including ODM-201, prior to study entry is allowed.
  • Patients who received Radium-223 are eligible for this study
  • Treatment with LHRH should not be discontinued.

Exploratory assessments:

CT-Scan (abdominal/pelvic/chest) or whole body MRI and Bone scan: at screening, every 3 months and EOT.

FACT-P questionnaire:at C1D1,each subsequent visit and EOT

Number of subjects:

Total:170 (85 per arm)

Statistical analysis:

A sample size of 77 evaluable patients per arm will achieve 80% power to detect a 20% difference in G3 neutropenia incidence between the 2 arms. The incidence in group cabazitaxel 25 mg/m2 q3w is assumed to be 32% and 12% on bi-weekly cabazitaxel arm. The test used is a two-sided Fisher's exact test at 0.05 significance level. Assuming 10% non-evaluable patients, 85 patients should be included in each arm for a total of 170. Patients will be stratified according to G8 score and previous ARtargeted agent (abiraterone or enzalutamide) before randomization.

Clinical Study Identifier: NCT02961257

Find a site near you

Start Over

CHU de Rouen

Rouen, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.